Bio-Connect

SIGMAR1 antibody [N1C3]

GTX115389
GeneTex
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetSIGMAR1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    SIGMAR1 antibody [N1C3]
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1.24 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID10280
  • Target name
    SIGMAR1
  • Target description
    sigma non-opioid intracellular receptor 1
  • Target synonyms
    ALS16, DSMA2, HMNR2, OPRS1, SIG-1R, SR-BP, SR-BP1, SRBP, hSigmaR1, sigma1R, sigma non-opioid intracellular receptor 1, SR31747 binding protein 1, aging-associated gene 8 protein, sigma 1-type opioid receptor
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ99720
  • Protein Name
    Sigma non-opioid intracellular receptor 1
  • Scientific Description
    This gene encodes a receptor protein that interacts with a variety of psychotomimetic drugs, including cocaine and amphetamines. The receptor is believed to play an important role in the cellular functions of various tissues associated with the endocrine, immune, and nervous systems. As indicated by its previous name, opioid receptor sigma 1 (OPRS1), the product of this gene was erroneously thought to function as an opioid receptor; it is now thought to be a non-opioid receptor. Alternative splicing of this gene results in transcript variants encoding distinct isoforms. [provided by RefSeq]
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • Yeh CH, Chen J, Zheng G, et al. Novel Pyropheophorbide Phosphatydic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment. Pharmaceutics. 2021,13(9). doi: 10.3390/pharmaceutics13091435
    Read this paper
  • Rennekamp AJ, Huang XP, Wang Y, et al. σ1 receptor ligands control a switch between passive and active threat responses. Nat Chem Biol. 2016,12(7):552-8. doi: 10.1038/nchembio.2089
    Read this paper
  • Lecaros RL, Huang L, Lee TC, et al. Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Mol Ther. 2016,24(1):106-16. doi: 10.1038/mt.2015.169
    Read this paper
  • Chen WH, Lecaros RL, Tseng YC, et al. Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett. 2015,359(1):65-74. doi: 10.1016/j.canlet.2014.12.052
    Read this paper